Clinical trials: Allergic Rhinoconjunctivitis
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Exposure Unit Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01385800
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
Phase III Cat-PAD Study
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
- Trial name
- NCT01620762
- Testing
- Cat-PAD
- Where
- 118 sites in United States, Belgium and 7 more
- Volunteers
- 1,408 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinitis, Hay Fever
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
- Trial name
- NCT00574379
- Testing
- Bilastine
- Where
- 13 sites in United States
- Volunteers
- 805 people
- Sponsor
- Faes Farma, S.A.
Allergic Rhinoconjunctivitis, Birch Pollen Allergy
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Allergic rhinoconjunctivitis due to birch pollen is a seasonal problem which manifests as a combination of nasal symptoms (such as congestion, runny nose, sneezing, itching of the nose) and ocular symptoms (such as red, itchy and…
- Trial name
- YOBI (NCT05668390)
- Testing
- STALORAL® Birch 300 IR
- Where
- 62 sites in Austria, Bulgaria and 10 more
- Volunteers
- 553 people
- Sponsor
- Stallergenes Greer
Allergic Rhinoconjunctivitis
A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
This is a continuing research study of a vaccine for allergy to Japanese Red Cedar. The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine.
- Trial name
- NCT01966224
- Testing
- CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Immunomic Therapeutics, Inc.
Mite Allergy, Dermatophagoides Farinae Allergy
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with…
- Conditions
- Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic
- Trial name
- NCT07427576
- Testing
- Clustoid® Max Forte
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Inmunotek S.L.
Allergies
Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration
Evaluation of patch as specific immunotherapy in allergic patients
- Trial name
- NCT00719511
- Testing
- Purified allergen dose 1 integrated in a Patch system, Purified allergen dose 2 integrated in a Patch system, Purified allergen dose 3 integrated in a Patch system
- Where
- Switzerland
- Volunteers
- 132 people
- Sponsor
- University of Zurich
Rhinitis, Allergic, Rhinoconjunctivitis, Allergic
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without…
- Trial name
- NCT03758456
- Testing
- HAL-MRE1
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- HAL Allergy
Birch Pollen Induced Rhinitis/Rhinoconjunctivitis
SUBLIVAC FIX Birch Phase III Short-term Efficacy
The aim of this phase III study is to asses if SUBLIVAC FIX Birch is safe and effective in reducing birch allergy induced symptoms and birch allergy medication usage.
- Trial name
- NCT02231307
- Testing
- SUBLIVAC FIX Birch
- Where
- 40 sites in Belgium, Czechia and 3 more
- Volunteers
- 406 people
- Sponsor
- HAL Allergy
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinoconjunctivitis
Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis
This is a comparative, open label, parallel group, non interventional study to further demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops.
- Trial name
- NCT02131051
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Bitop AG
Rhinitis, Allergic, Seasonal
Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever
The purpose of this study is to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge.
- Trial name
- NCT00135629
- Testing
- Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ)., Venepuncture: 100ml blood sample taken on 12 separate visits
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks.
- Trial name
- NCT01144429
- Testing
- Allergoid, allergenic extract of 100% Birch
- Where
- 39 sites in Germany, Lithuania and 1 more
- Volunteers
- 344 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinitis
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.
- Trial name
- NCT01012531
- Testing
- Subcutaneous injections with highly polymerized allergen extract
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Roxall Medizin
Allergy
Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children
Allergic rhinoconjunctivitis is a pathology of the nasal and conjunctival mucosa induced by Immunoglobulin E (IgE) mediated inflammation following allergic exposure.
- Trial name
- NCT03449836
- Testing
- Streptococcus salivarius 24SMBc + Strept. oralis 89a, fluticasone + mometasone
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Allergic Rhinoconjunctivitis, Allergic Rhinitis
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
- Trial name
- NCT07060885
- Testing
- HDM SLIT-tablet (12 SQ-HDM)
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- ALK-Abelló A/S
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
Ragweed Allergy, Rhinoconjunctivitis
ToleroMune Ragweed Follow up Study
Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more…
- Trial name
- NCT01448603
- Testing
- ToleroMune Ragweed
- Where
- Canada
- Volunteers
- 109 people
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis
Probiotic Chewables in Allergic Rhinoconjunctivitis Patients
With this double- blind, randomised, placebo-controlled study, the investigators want to investigate the influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the symptoms and immunological markers…
- Trial name
- NCT04898686
- Testing
- Probiotic chewables
- Where
- Belgium
- Volunteers
- 64 people
- Sponsor
- University Hospital, Antwerp
Allergic Asthma, Thunderstorm Asthma
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen.
- Conditions
- Allergic Asthma, Thunderstorm Asthma, Seasonal Allergic Rhinitis, Grass Pollen Allergy
- Trial name
- CARISTA (NCT07055542)
- Testing
- Observational
- Where
- 6 sites in Australia
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- University of Melbourne